Pharma Mar S A : GENOMICA, PharmaMar Group, announces that they have validated their PCR testing kit for saliva based sampling

GENOMICA, PharmaMar Group, announces that they have validated their PCR testing kit for saliva based sampling

• Saliva sampling would significantly reduce the exposure and risks of healthcare personnel during sampling
• The need for a laboratory extraction kit disappears, saving time and costs.
• The evaluation was carried out within the framework of the COVID-LOT study, headed by the Complutense University, Madrid.

Madrid, January 28th, 2021. - GENOMICA, a wholly owned molecular diagnostics Company of PharmaMar Group (MSE:PHM), announces that it has validated its qCOVID-19Respiratory COMBO kit for use with saliva samples. This kit is capable of deecting SARS-CoV-2in saliva samples.

The use of saliva simplifies the sampling process, reducing possible contact, significantly diminishes exposure and potential risks of infection during the sampling process. In the laboratory, the direct use of saliva for the PCR's eliminates the need to perform a nasopharyngeal extraction, which constitutes a current bottleneck in many laboratories.

Thanks to these innovations, GENOMICA's kit provides advantages over other PCR kits currently on the market, which, in practice, will save valuable time and cost in obtaining results.

This validation allows an increase in the type of samples accepted for the qCOVID-19 Respiratory Combo PCR kit, which besides nasopharyngeal exudate now also includes saliva sampling as a means of SARS-CoV-2 detection. The data was obtained within the framework of the collaboration in the COVID-LOT project, a study led by the Complutense University of Madrid and headed by Dr. Francisco Javier Arroyo, Dr. José Manuel Bautista and Dr. Jesús Pérez-Gil in the coordination and scientific management.

The project compared results from 72 simultaneously obtained nasopharyngeal and saliva samples. The analysis of COVID-19 with GENOMICA's PCR test obtained a sensitivity of 100%, even allowing for the detection of asymptomatic cases.

The qCOVID 19 Respiratory Combo test, which is now increasing its number of applications, was launched in November 2020 and is based on real-time PCR or qPCR. The inclusion of saliva sampling enables a rapid and accurate diagnosis, allowing physicians to classify patients, determining the most appropriate treatment and isolation measures for each case.

GENOMICA has commercial agreements in more than 20 countries around the globe.

The Company remains committed to supplying Spanish institutions. Since the launch of the first PCR kit for COVID-19 with the CE conformity marking, thousands of patients have been tested for SARS-CoV-2 with GENOMICA's kits, which are manufactured at its facilities in Madrid. Now, this new development will provide both Spanish and international hospitals with a new method against COVID-19, assisting in a rapid and accurate diagnosis.

Coronaviruses are a widespread family of viruses that can cause the common cold, but also more serious illnesses such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS).

For more information on qCOVID-19Respiratory COMBO, please contact the GENOMICA team at [e-mail] information is also available on genomica.com.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About GENOMICA

GENOMICA is highly experienced in the analysis of genetic identification. Founded in 1990, with facilities in Madrid, GENOMICA is 100% owned by PharmaMar. It is our mission to improve the present molecular diagnostics tools and the human identification methods through reliability and automation.

Our main objective is to maintain leadership in genomics applications within the Spanish market, and to internationally extend our activities in the area of Molecular Diagnostics by means of the design, development, automation, and commercialization of new diagnostic applications of our innovative technological platform, Clinical Arrays Technology, CLART®.

Media Contact:

Alfonso Ortín - Communications Director [e-mail]: [phone]

Miguel Martínez-Cava-Communication Manager [e-mail]: [phone]

Phone: [phone]

Capital Markets & Investor Relations:

José Luis Moreno- Capital Markets & Investor Relations Director María Marín de la Plaza - Capital Markets & Investor Relations [e-mail]

Phone: [phone]

Or please visit our website at www.pharmamar.com